<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">WATANABE, DAICHI</style></author><author><style face="normal" font="default" size="100%">FUJII, HIRONORI</style></author><author><style face="normal" font="default" size="100%">MATSUHASHI, NOBUHISA</style></author><author><style face="normal" font="default" size="100%">IIHARA, HIROTOSHI</style></author><author><style face="normal" font="default" size="100%">YAMADA, YUNAMI</style></author><author><style face="normal" font="default" size="100%">ISHIHARA, TAKUMA</style></author><author><style face="normal" font="default" size="100%">TAKAHASHI, TAKAO</style></author><author><style face="normal" font="default" size="100%">YOSHIDA, KAZUHIRO</style></author><author><style face="normal" font="default" size="100%">SUZUKI, AKIO</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Dose Adjustment of Oxaliplatin Based on Renal Function in Patients With Metastatic Colorectal Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">2379-2386</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.14207</style></doi><volume><style face="normal" font="default" size="100%">40</style></volume><issue><style face="normal" font="default" size="100%">4</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: The effect of renal dysfunction on the toxicity and efficacy of oxaliplatin remains unclear. We investigated the association between creatinine clearance (Ccr), a marker of renal function, and the toxicity and efficacy of oxaliplatin in patients with metastatic colorectal cancer (mCRC). Patients and Methods: Patients with mCRC who received oxaliplatin-based chemotherapy as first-line treatment were included in this study. Primary outcome was peripheral neuropathy (Grade ≥2), while secondary outcomes included neutropenia (Grade ≥3), thrombocytopenia (Grade ≥2) and overall survival (OS). Results: A total of 145 patients with mCRC were eligible. Incidence rates of peripheral neuropathy (Grade ≥2), neutropenia (Grade ≥3) and thrombocytopenia (Grade ≥2) were 30.3%, 37.2% and 16.6%, respectively, and median OS was 29.1 months. Cox proportional hazards analysis indicated that there was no significant relationship between Ccr and any adverse event, or between Ccr and OS. Conclusion: Dose reduction of oxaliplatin based on Ccr is not recommended in patients with mCRC.</style></abstract></record></records></xml>